nach oben

Erschienen in:

06.11.2019

Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds

verfasst von: Florian Härtig, Sven Poli, Matthias Ebner, Ingvild Birschmann, Joachim Kuhn, Ulf Ziemann, Hans-Ulrich Häring, Rainer Lehmann, Andreas Peter, Sebastian Hörber

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

The direct oral anticoagulant dabigatran does not require therapeutic drug monitoring, however emergency measurements are gaining importance. Current assays feature good performance at intermediate and high dabigatran concentrations but show limited accuracy at low concentrations. This area requires more attention as clinical decision threshold values currently lie at 30 and 50 ng/ml. The objective of the study was to evaluate and compare diagnostic performance of dabigatran assays at these thresholds. Dabigatran concentrations of 293 plasma samples taken from 50 patients were measured with the INNOVANCE direct thrombin inhibitor assay (DTI) from Siemens, the Biophen direct thrombin inhibitor assay (BDTI), the BDTI using a low range calibrator (BDTI-low), the Hemoclot direct thrombin inhibitor assay (HTI) and an ecarin clotting time assay (ECT). Assay results were compared to ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), and test characteristics were calculated for thresholds of 30 and 50 ng/ml. DTI, BDTI-low and ECT showed very strong correlation and high agreement with UPLC-MS/MS and an improved determination of low dabigatran concentrations. ROC curve analyses revealed very high accuracy at the 30/50 ng/ml thresholds for DTI (AUC = 0.989/0.995), BDTI-low (AUC = 0.980/0.991) and ECT (AUC = 0.990/0.996) measurements. Sensitivity and specificity in detecting were calculated for DTI (98/92%), BDTI-low (87/95%), ECT (97/96%), BDTI (99/82%) and HTI (86/89%) measurements. Compared to the previously available HTI and BDTI, both novel assays, DTI and BDTI-low, reliably determine low dabigatran plasma concentrations around the clinical decision thresholds with very high sensitivity and specificity.

Nur mit Berechtigung zugänglich

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561 CrossRefPubMed

Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352. https://doi.org/10.1056/NEJMoa0906598 CrossRefPubMed

Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ, Investigators R-MT, Investigators R-ST (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368(8):709–718. https://doi.org/10.1056/NEJMoa1113697 CrossRefPubMed

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962. https://doi.org/10.1016/S0140-6736(13)62343-0 CrossRefPubMed

Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK, GARFIELD-AF Investigators (2016) Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Br J Haematol 174(4):610–623. https://doi.org/10.1111/bjh.14084 CrossRefPubMed

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962. https://doi.org/10.1093/eurheartj/ehw210 CrossRefPubMed

Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, ESC Scientific Document Group (2017) Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 38(27):2137–2149. https://doi.org/10.1093/eurheartj/ehw058 CrossRefPubMed

Tripodi A (2013) The laboratory and the new oral anticoagulants. Clin Chem 59(2):353–362. https://doi.org/10.1373/clinchem.2012.189704 CrossRefPubMed

Kitchen S, Gray E, Mackie I, Baglin T, Makris M, committee B (2014) Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol 166(6):830–841. https://doi.org/10.1111/bjh.12975 CrossRefPubMed

10.

Levy JH (2016) Discontinuation and management of direct-acting anticoagulants for emergency procedures. Am J Med 129(11S):S47–S53. https://doi.org/10.1016/j.amjmed.2016.06.005 CrossRefPubMed

11.

Wright C, Brown R, Cuker A (2017) Laboratory measurement of the direct oral anticoagulants: indications and impact on management in clinical practice. Int J Lab Hematol 39(Suppl 1):31–36. https://doi.org/10.1111/ijlh.12654 CrossRefPubMed

12.

Martin K, Moll S (2016) Direct oral anticoagulant drug level testing in clinical practice: a single institution experience. Thromb Res 143:40–44. https://doi.org/10.1016/j.thromres.2016.04.019 CrossRefPubMedPubMedCentral

13.

Ahmed N, Steiner T, Caso V, Wahlgren N (2017) Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13–15 November 2016. Eur Stroke J 2 (2):95–102. https://doi.org/10.1177/2396987317699144 CrossRefPubMedPubMedCentral

14.

Pollack CV Jr, Reilly PA, Weitz JI (2017) Dabigatran reversal with idarucizumab. N Engl J Med 377(17):1691–1692. https://doi.org/10.1056/NEJMc1711337 CrossRefPubMed

15.

Litwinowicz R, Konstanty-Kalandyk J, Goralczyk T, Bartus K, Mazur P (2018) Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery. J Thromb Thrombolysis 45(1):9–12. https://doi.org/10.1007/s11239-017-1587-9 CrossRefPubMed

16.

Ebner M, Peter A, Spencer C, Hartig F, Birschmann I, Kuhn J, Wolf M, Winter N, Russo F, Zuern CS, Blumenstock G, Ziemann U, Poli S (2015) Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants. Stroke 46(10):2741–2747. https://doi.org/10.1161/STROKEAHA.115.010148 CrossRefPubMed

17.

Ebner M, Birschmann I, Peter A, Hartig F, Spencer C, Kuhn J, Blumenstock G, Zuern CS, Ziemann U, Poli S (2017) Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions. Stroke 48(9):2457–2463. https://doi.org/10.1161/STROKEAHA.117.017981 CrossRefPubMed

18.

Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Ronquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogne JM, Mullier F (2015) Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost 113(4):862–869. https://doi.org/10.1160/TH14-09-0808 CrossRefPubMed

19.

Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S (2018) International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 118(3):437–450. https://doi.org/10.1055/s-0038-1627480 CrossRefPubMed

20.

van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116–1127. https://doi.org/10.1160/TH09-11-0758 CrossRefPubMed

21.

Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, van der Graaf F, Brunsveld L, van de Kerkhof D (2014) Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 12(10):1636–1646. https://doi.org/10.1111/jth.12702 CrossRefPubMed

22.

Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107(5):985–997. https://doi.org/10.1160/TH11-11-0804 CrossRefPubMed

23.

Poli S, Hartig F, Spencer C, Ebner M, Birschmann I, Kuhn J, Faix S, Ziemann U, Haring HU, Lehmann R, Peter A, Horber S (2017) Diagnostic accuracy of a novel chromogenic direct thrombin inhibitor assay: clinical experiences for dabigatran monitoring. Thromb Haemost 117(12):2369–2375. https://doi.org/10.1160/TH17-04-0280 CrossRefPubMed

24.

Kuhn J, Gripp T, Flieder T, Dittrich M, Hendig D, Busse J, Knabbe C, Birschmann I (2015) UPLC-MRM mass spectrometry method for measurement of the coagulation inhibitors dabigatran and rivaroxaban in human plasma and its comparison with functional assays. PLoS ONE 10(12):e0145478. https://doi.org/10.1371/journal.pone.0145478 CrossRefPubMedPubMedCentral

25.

Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods Med Res 8(2):135–160CrossRefPubMed

26.

DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845CrossRefPubMed

27.

Jaffer IH, Chan N, Roberts R, Fredenburgh JC, Eikelboom JW, Weitz JI (2017) Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. J Thromb Haemost 15(12):2377–2387. https://doi.org/10.1111/jth.13857 CrossRefPubMed

28.

Cini M, Legnani C, Cosmi B, Testa S, Dellanoce C, Paoletti O, Marcucci R, Poli D, Paniccia R, Pengo V, Tripodi A, Palareti G, Register ST-L (2018) Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register. Int J Lab Hematol 40(2):229–236. https://doi.org/10.1111/ijlh.12772 CrossRefPubMed

29.

Bozic-Mijovski M, Malmstrom RE, Malovrh P, Antovic JP, Vene N, Sinigoj P, Mavri A (2016) Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations. Ann Clin Biochem 53(Pt 4):446–451. https://doi.org/10.1177/0004563215599795 CrossRefPubMed

30.

Flieder T, Hammerschmidt A, Kuhn J, Knabbe C, Birschmann I (2018) Evaluation of DOAC measurement on the CS-5100 using the INNOVANCE(R) Heparin and INNOVANCE(R) DTI reagent. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-018-1675-5 CrossRefPubMed

31.

Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sie P, Working Group on Perioperative H (2013) Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March 2013. Arch Cardiovasc Dis 106(6–7):382–393. https://doi.org/10.1016/j.acvd.2013.04.009 CrossRefPubMed

32.

Godier A, Martin AC, Leblanc I, Mazoyer E, Horellou MH, Ibrahim F, Flaujac C, Golmard JL, Rosencher N, Gouin-Thibault I (2015) Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations. Thromb Res 136(4):763–768. https://doi.org/10.1016/j.thromres.2015.08.006 CrossRefPubMed

33.

Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Rother J, Schellinger PD, Spannagl M, Veltkamp R (2013) Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 102(6):399–412. https://doi.org/10.1007/s00392-013-0560-7 CrossRefPubMed

34.

Rottenstreich A, Zacks N, Kleinstern G, Raccah BH, Roth B, Da'as N, Kalish Y (2018) Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-018-1643-0 CrossRefPubMed

35.

Chan N, Sager PT, Lawrence J, Ortel T, Reilly P, Berkowitz S, Kubitza D, Eikelboom J, Florian J, Stockbridge N, Rose M, Temple R, Seltzer JH (2018) Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants? Am Heart J 199:59–67. https://doi.org/10.1016/j.ahj.2017.10.002 CrossRefPubMed

36.

Reiffel JA, Weitz JI, Reilly P, Kaminskas E, Sarich T, Sager P, Seltzer J, Cardiac Safety Research Consortium presenters and participants (2016) NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: a cardiac safety research consortium think tank. Am Heart J 177:74–86. https://doi.org/10.1016/j.ahj.2016.04.010 CrossRefPubMed

37.

Winther-Larsen A, Hvas AM (2019) Clinical impact of direct oral anticoagulant measuring in a real-life setting. Thromb Res 175:40–45. https://doi.org/10.1016/j.thromres.2019.01.016 CrossRefPubMed

38.

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373(6):511–520. https://doi.org/10.1056/NEJMoa1502000 CrossRefPubMed

39.

Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, Douketis JD, Schulman S, Eikelboom JW (2015) Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 13(3):353–359. https://doi.org/10.1111/jth.12823 CrossRefPubMed

40.

Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292–303. https://doi.org/10.1111/j.1365-2125.2007.02899.x CrossRefPubMedPubMedCentral

41.

Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, Investigators R-L (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63(4):321–328. https://doi.org/10.1016/j.jacc.2013.07.104 CrossRefPubMed

Titel: Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds
verfasst von: Florian Härtig
Sven Poli
Matthias Ebner
Ingvild Birschmann
Joachim Kuhn
Ulf Ziemann
Hans-Ulrich Häring
Rainer Lehmann
Andreas Peter
Sebastian Hörber
Publikationsdatum: 06.11.2019
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 3/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-019-01981-z

The impact of incidental pulmonary cement embolism on mortality risk

Self-rated health and venous thromboembolism among middle-aged women: a population-based cohort study

Open Access

Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis

β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease

Clopidogrel

Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience

Management of venous thromboembolism in patients experiencing direct oral anticoagulant treatment failure: a single-center review of practice and outcomes

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mit Lidocain kommt der Darm nicht schneller in Schwung

13.01.2025
Kolektomie
Nachrichten

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Koronare Herzkrankheit: Das waren die Top-Studien in 2024

12.01.2025
Koronare Herzerkrankung
Nachrichten

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

10.01.2025
Mammakarzinom
Nachrichten

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Inhalative Steroide bei COPD nicht kardioprotektiv

10.01.2025
COPD
Nachrichten

Ob inhalative Kortikosteroide (ICS) COPD-Kranke außer vor akuten Exazerbationen auch vor kardiovaskulären Komplikationen schützen können, ist unklar. Eine bevölkerungsbasierte Studie aus England spricht nicht dafür.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds

Abstract

Weitere Artikel der Ausgabe 3/2020

The impact of incidental pulmonary cement embolism on mortality risk

Self-rated health and venous thromboembolism among middle-aged women: a population-based cohort study

Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis

β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease

Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience

Management of venous thromboembolism in patients experiencing direct oral anticoagulant treatment failure: a single-center review of practice and outcomes

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

Mit Lidocain kommt der Darm nicht schneller in Schwung

Koronare Herzkrankheit: Das waren die Top-Studien in 2024

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Inhalative Steroide bei COPD nicht kardioprotektiv

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten